search
Back to results

Physical Therapies in the Decongestive Treatment of Lymphedema

Primary Purpose

Primary Lymphedema, Secondary Lymphedema

Status
Completed
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Manual Lymphatic Drainage (MLD)
Generic intermittent pneumatic compression Device (IPC)
multilayer, multicomponent bandages (MB)
Lymphapress-Plus(TM) device (LPD)
Sponsored by
Isabel Forner-Cordero, MD, PhD.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Primary Lymphedema focused on measuring Lymphedema, Physical Therapies, Randomized controlled study, Decongestive lymphatic therapy, Manual lymph drainage, Intermittent pneumatic compression, Multilayer bandages

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • primary or secondary lymphedema,
  • lymphedema stages II or III
  • affecting unilateral upper or lower limb
  • Excess volume (EV) > 10%

Exclusion Criteria:

  • malignancy or active neoplasm disease or lack of information about it.
  • active lymphangitis
  • known contraindications for Decongestive Lymphatic Therapy (DLT): renal insufficiency, uncontrolled hypertension, cardiac disease and venous thrombosis.
  • a course of DLT during last year.
  • anything that could alter the patient's capability to consent truly to participate in this study

Sites / Locations

  • University Hospital La Fe

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Experimental

Experimental

Arm Label

Standard trimodality therapy with MLD

Trimodality therapy with LPD

Bimodality therapy without MLD

Arm Description

Manual Lymphatic Drainage (MLD) followed by intermittent pneumatic compression (IPC) and followed by multilayer, multicomponent bandages (MB) until next day.

Pneumatic massage with Lymphapress-Plus(TM) device (LPD) followed by intermittent pneumatic compression (IPC) and followed by multilayer, multicomponent bandages (MB) until next day

intermittent pneumatic compression (IPC) followed by multilayer, multicomponent bandages (MB) until next day.

Outcomes

Primary Outcome Measures

Percentage reduction in Excess Volume (PREV)
It is obtained with the following formula: [(Initial EV - Final EV)/ Initial EV] x 100; where Excess Volume (EV) is the difference between Lymphedematous (VL) and Healthy limb volume (VH). Volumes were calculated with tape perimeter measurements (C) taken from the dorsum of the hand (C1) and repeated for every 4 cm proximally until the axilla (Cn), using Kuhnke formula, as the disk model is considered the method of choice in clinical practice. We assessed the change from baseline in PREV during Decongestive Lymphedema Treatment (DLT)and during 12 months of follow-up after DLT.

Secondary Outcome Measures

the Percentage of Volume reduction (PRV)
it was calculated with the following formula: [(Initial VL - Final VL)/ Initial VL] x 100. We assessed the change from baseline in PRV during Decongestive Lymphedema Treatment (DLT)and during 12 months of follow-up after DLT.

Full Information

First Posted
December 6, 2012
Last Updated
December 16, 2012
Sponsor
Isabel Forner-Cordero, MD, PhD.
search

1. Study Identification

Unique Protocol Identification Number
NCT01748604
Brief Title
Physical Therapies in the Decongestive Treatment of Lymphedema
Official Title
Physical Therapies in the Decongestive Treatment of Lymphedema: A Multicenter, Randomized, Controlled Study.
Study Type
Interventional

2. Study Status

Record Verification Date
December 2012
Overall Recruitment Status
Completed
Study Start Date
February 2004 (undefined)
Primary Completion Date
January 2010 (Actual)
Study Completion Date
June 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Isabel Forner-Cordero, MD, PhD.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this multicenter randomised controlled study is to determine whether manual lymphatic drainage (MLD) brings any benefit when added to intermittent pneumatic compression (IPC) plus multilayer, multicomponent bandages (MB) in the decongestive lymphatic therapy (DLT) in patients with lymphedema
Detailed Description
Study Design: the study was a multicenter, randomized controlled study conducted at three university hospitals in Spain. Potential subjects were identified at Rehabilitation Department where physicians were responsible for screening subjects for eligibility and enrolling into the study. Patients that fulfilled the inclusion criteria and signed up the informed consent were stratified within 2 stratums, upper and lower limb lymphedema, and then were randomized to one of the three treatment groups. The type of randomization was a total randomization with ratio 1:1:1 and the method used to generate the random allocation sequence was a computer-generated random numbers table. Adequate randomization includes calling a central office once eligibility has been determined. The physicians that assessed the outcome and the statistic who analyzed de data were blinded to the subjects' treatment assignment. The study was approved by the Research Ethics Committee of the University Hospital La Fe. It was conducted according to the ethical principles laid down in the declaration of Helsinki (52nd World Medical Association General Assembly, Edinburgh, Scotland, October 2000) and the rules of best clinical practice. Treatment Regimens: Patients were randomized to one of the following treatment groups: Group A or control group: Manual Lymphatic Drainage (MLD) with Földi's technique by an expert therapist during 45 minutes; intermittent pneumatic compression (IPC) with multicompartmental pump between 50 to 80 mmHg during 30 minutes, followed by multilayer, multicomponent bandages (MB) until next day. Group B: Pneumatic massage with Lymphapress-Plus(TM) device that was lent during the duration of the study during 20 minutes, and was supposed to open the proximal lymphatics at the root of the limb; IPC (50 to 80 mmHg during 30 minutes), followed by MB until next day. Group C: IPC (50 to 80 mmHg during 30 minutes) followed by MB until next day. All patients were planned to receive 20 sessions of treatment (5 per week in consecutive days during 4 consecutive weeks) and were trained in skin care and daily exercises. After DLT, garments were prescribed and their adaptation was checked to warrant the maintenance of the results. The garments were flat knitted, custom made, generally class 2 (18-21 mmHg) for upper limb, and class 3 (36-46 mmHg) for lower limb. Sample Size and Statistical analyses: This trial compares the efficacy of two treatment modalities without MLD (experimental group B and C) with a standard trimodal therapy (control group A). The expected effect size in percentage reduction in excess volume (PREV), primary end point, for the control group (MLD+IPC+MB) was defined from the review of literature and was 50 to 70% (mean 60%) with a standard deviation of 20 to 30 (mean 25). Our hypothesis was that there are no differences between experimental and standard treatment. The required sample size for the study was 177 patients or 59 subjects per group to detect differences greater than or equal 15% in the percentage reduction in excess volume (PREV) between control and experimental groups, if exists; considering differences less than 15% as not clinically significant. It was based on an alpha error of 5% and a power of 90%. We estimated a drop-out rate of 10%. Therefore, 17 patients were added, resulting in a sample size of 194 subjects. To compare baseline characteristics between three groups we use two-way ANOVA test for continuous variable and Pearson's chi2 for categorical data, to detect potential confounding factors. Outcome data were analyzed utilizing a two-way ANOVA test to assess differences between treatment groups with a 5% level of significance (p≤0.05) and two-tailed tests. An exploratory subgroup analysis was made to identify factors associated with response (PREV). Factors for initial screening were identified by univariate linear regression model with a p value <0.1. In order to determine the independent predictive factors, a multivariate linear regression analysis was applied.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Primary Lymphedema, Secondary Lymphedema
Keywords
Lymphedema, Physical Therapies, Randomized controlled study, Decongestive lymphatic therapy, Manual lymph drainage, Intermittent pneumatic compression, Multilayer bandages

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
194 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Standard trimodality therapy with MLD
Arm Type
Active Comparator
Arm Description
Manual Lymphatic Drainage (MLD) followed by intermittent pneumatic compression (IPC) and followed by multilayer, multicomponent bandages (MB) until next day.
Arm Title
Trimodality therapy with LPD
Arm Type
Experimental
Arm Description
Pneumatic massage with Lymphapress-Plus(TM) device (LPD) followed by intermittent pneumatic compression (IPC) and followed by multilayer, multicomponent bandages (MB) until next day
Arm Title
Bimodality therapy without MLD
Arm Type
Experimental
Arm Description
intermittent pneumatic compression (IPC) followed by multilayer, multicomponent bandages (MB) until next day.
Intervention Type
Other
Intervention Name(s)
Manual Lymphatic Drainage (MLD)
Intervention Description
MLD with Földi's technique by an expert therapist during 45 minutes
Intervention Type
Device
Intervention Name(s)
Generic intermittent pneumatic compression Device (IPC)
Intervention Description
Generic intermittent pneumatic compression with multicompartmental pump between 50 to 80 mmHg during 30 minutes.
Intervention Type
Other
Intervention Name(s)
multilayer, multicomponent bandages (MB)
Intervention Description
multilayer, multicomponent bandages (MB) until next day.
Intervention Type
Device
Intervention Name(s)
Lymphapress-Plus(TM) device (LPD)
Intervention Description
Pneumatic massage with Lymphapress-Plus(TM)device that was lent during the duration of the study during 20 minutes.
Primary Outcome Measure Information:
Title
Percentage reduction in Excess Volume (PREV)
Description
It is obtained with the following formula: [(Initial EV - Final EV)/ Initial EV] x 100; where Excess Volume (EV) is the difference between Lymphedematous (VL) and Healthy limb volume (VH). Volumes were calculated with tape perimeter measurements (C) taken from the dorsum of the hand (C1) and repeated for every 4 cm proximally until the axilla (Cn), using Kuhnke formula, as the disk model is considered the method of choice in clinical practice. We assessed the change from baseline in PREV during Decongestive Lymphedema Treatment (DLT)and during 12 months of follow-up after DLT.
Time Frame
at 10 sessions of DLT (2 weeks), at 20 sessions of DLT (4 weeks) and at 1, 6 and 12 months after the end of DLT
Secondary Outcome Measure Information:
Title
the Percentage of Volume reduction (PRV)
Description
it was calculated with the following formula: [(Initial VL - Final VL)/ Initial VL] x 100. We assessed the change from baseline in PRV during Decongestive Lymphedema Treatment (DLT)and during 12 months of follow-up after DLT.
Time Frame
at 10 sessions of DLT (2 weeks), at 20 sessions of DLT (4 weeks) and at 1, 6 and 12 months after the end of DLT
Other Pre-specified Outcome Measures:
Title
Adverse events related to the treatment
Description
Discomfort Lymphangitis attacks Edema displacement Fibrosclerotic ring Loss of mobility
Time Frame
at 10 sessions of DLT (2 weeks), at 20 sessions of DLT (4 weeks) and at 1, 6 and 12 months after the end of DLT

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: primary or secondary lymphedema, lymphedema stages II or III affecting unilateral upper or lower limb Excess volume (EV) > 10% Exclusion Criteria: malignancy or active neoplasm disease or lack of information about it. active lymphangitis known contraindications for Decongestive Lymphatic Therapy (DLT): renal insufficiency, uncontrolled hypertension, cardiac disease and venous thrombosis. a course of DLT during last year. anything that could alter the patient's capability to consent truly to participate in this study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Isabel I Forner-Cordero, MD, Phd
Organizational Affiliation
University Hospital La Fe
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Jose J Muñoz-Langa, MD, Phd
Organizational Affiliation
University Hospital Dr Peset
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital La Fe
City
Valencia
ZIP/Postal Code
46026
Country
Spain

12. IPD Sharing Statement

Citations:
PubMed Identifier
9664269
Citation
Johansson K, Lie E, Ekdahl C, Lindfeldt J. A randomized study comparing manual lymph drainage with sequential pneumatic compression for treatment of postoperative arm lymphedema. Lymphology. 1998 Jun;31(2):56-64.
Results Reference
background
PubMed Identifier
15319562
Citation
McNeely ML, Magee DJ, Lees AW, Bagnall KM, Haykowsky M, Hanson J. The addition of manual lymph drainage to compression therapy for breast cancer related lymphedema: a randomized controlled trial. Breast Cancer Res Treat. 2004 Jul;86(2):95-106. doi: 10.1023/B:BREA.0000032978.67677.9f.
Results Reference
background
PubMed Identifier
15495042
Citation
Badger C, Preston N, Seers K, Mortimer P. Physical therapies for reducing and controlling lymphoedema of the limbs. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD003141. doi: 10.1002/14651858.CD003141.pub2.
Results Reference
background

Learn more about this trial

Physical Therapies in the Decongestive Treatment of Lymphedema

We'll reach out to this number within 24 hrs